Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL

• Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and…

‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7

@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct

So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face. Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work! #ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM

• David Liew on Twitter: "Looking forward to hearing it presented by @Sattui…

Factors associated w/ poor COVID19 outcomes in #SLE from the GRA @rheum_covid 📌Demographics - age, sex, region 📌Glucocorticoid use 📌 Comorbids - renal, CV 📌Untreated/active dse ❗Very important msg here: Control dse, manage comorbids & avoid GCs @RheumNow #ACR21 abs0866 https://t.co/eXR3KqGrJa

Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs